| 000 | 01828 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514062324.0 | ||
| 264 | 0 | _c20030505 | |
| 008 | 200305s 0 0 ger d | ||
| 022 | _a0040-5930 | ||
| 024 | 7 |
_a10.1024/0040-5930.60.1.24 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTsakiris, D A | |
| 245 | 0 | 0 |
_a[New antiaggregants and their importance for the practitioner]. _h[electronic resource] |
| 260 |
_bTherapeutische Umschau. Revue therapeutique _cJan 2003 |
||
| 300 |
_a24-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnesthesia, Spinal |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAspirin _xadministration & dosage |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdrug therapy |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 | _aContraindications |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEptifibatide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPeptides _xadministration & dosage |
| 650 | 0 | 4 | _aPlacebos |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 |
_aTiclopidine _xadministration & dosage |
| 650 | 0 | 4 | _aTirofiban |
| 650 | 0 | 4 |
_aTyrosine _xadministration & dosage |
| 773 | 0 |
_tTherapeutische Umschau. Revue therapeutique _gvol. 60 _gno. 1 _gp. 24-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1024/0040-5930.60.1.24 _zAvailable from publisher's website |
| 999 |
_c12432980 _d12432980 |
||